Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer
Status:
Not yet recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Almonertinib Plus Pemetrexed and Carboplatin Versus Almonertinib Alone in Advanced NSCLC With
EGFR T790M After First- or Second-generation TKIs Therapy: a Randomized, Controlled,
Open-label, Phase 2 Study